Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Suspended 1Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Prostatic Neoplasms 9Glioblastoma 9Carcinoma, Non-Small-Cell Lung 7Lung Neoplasms 6Brain Neoplasms 6Glioma 5Breast Neoplasms 5Oligodendroglioma 4Neoplasm Metastasis 4Multiple Myeloma 4Colorectal Neoplasms 4Astrocytoma 4Squamous Cell Carcinoma of Head and Neck 3Pancreatic Neoplasms 3Neuroectodermal Tumors, Primitive 3Neoplasms 3Meningioma 3Medulloblastoma 3Gliosarcoma 3Glioma, Subependymal 3Ependymoma 3Central Nervous System Neoplasms 3Carcinoma, Renal Cell 3Sarcoma 2Platinum-Refractory Fallopian Tube Carcinoma 2Pinealoma 2Melanoma 2Lymphoma, Mantle-Cell 2Lymphoma 2Hematologic Neoplasms 2

Interventions

olaparib 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Biopsy 1Alpelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Anatomic Stage III Breast Cancer AJCC v8 × Magnetic Resonance Spectroscopy × Clear all
NCT05967286 2024-03-20

Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial

National Cancer Institute (NCI)

Phase 2 Withdrawn
Breast

Anatomic Stage III Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡